Abstract: This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE2 biosynthesis or PGE2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE2 include non-steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E2 (dmPGE2), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.

Abstract: Methods and compositions comprising hematopoietic growth factor proteins and/or protein analogs thereof and/or combinations thereof and angiotensin converting enzyme inhibitors to treat the acute and long term adverse effects of radiation exposure in subjects who have been or will be exposed to radiation are disclosed.

Abstract: Processes and methods for modifying the surface of graphitic carbon with covalently bonded chemcial groups and the treated graphitic carbon products of such processes are provided. Additionally, exemplary articles comprising such treated graphitic carbons are provided.

Abstract: Compositions and methods for therapeutic delivery are disclosed. More particularly, the present disclosure relates to nanoparticle compositions that sequester the activity of a target molecule while leaving other domains accessible to bind targeted tissues of interest. Methods for thrombus dissolution include administering a nanoparticle reversibly coupled to a target molecule that can dissolve a blood clot. Compositions and methods for inducing blood clotting are also disclosed. Methods for inducing blood clotting include administering a nanoparticle reversibly coupled to a target molecule that can induce the formation of a blood clot. Methods for sequestering a target molecule are also disclosed. The method includes reversibly coupling a target molecule to a nanoparticle having an affinity ligand that reversibly couples the target molecule, and thus, sequesters the target molecule activity until the target molecule interacts with its substrate resulting in the release of the target molecule.

Abstract: The present disclosure relates to certain compounds having binding affinity for XPA, and uses thereof. Specifically, the present disclosure relates to the use of XPA inhibitors as described herein in in methods of treating cancer.

Abstract: A system and methods utilizing electrical stimulation to achieve a desired therapeutic effect are provided. In one aspect, a method for controlling nerve activity in a subject is provided. The method includes receiving input indicating a desired therapeutic effect for at least one neural structure of a subject, and selecting, based on the input received, an electrical stimulation configured to achieve the desired therapeutic effect. The method also includes controlling a sympathetic nerve activity in the subject by delivering the electrical stimulation using electrodes positioned proximate to nerves innervating the subject's skin.

Abstract: A nerve activity blocking system (100) includes a blocking electrode (102) configured to generate a blocking electrical signal that blocks, at least in part, an action potential propagating through a nerve system of a body. using a low frequency alternating current. The blocking electrical signal prevents propagation of the action potential by overriding another electrical signal controlling an organ of the body.

Abstract: A prosthesis, radiation bolus, pre-surgical model, or burn mask formed using a rapid prototyping device, such as a three-dimensional printer. In some exemplary aspects, the prosthesis includes a scaffolding and a coating at least partially covering the scaffolding. Methods and systems for forming the prosthesis, radiation bolus, pre-surgical model, or burn mask are also provided.

Abstract: Disclosed herein are compositions for assessing peptidoglycan (PG) biosynthesis in bacteria using modified D-amino acids covalently attached to a molecular rotor and visualizing the labeled PG in bacteria based upon the enhanced fluorescence of the molecular rotor incorporated in the PG. The resultant, labeled peptidoglycan structures are amenable for identification by microscopic visualization, flow cytometry or other suitable methods.

Abstract: Compounds, compositions, and formulations, and accompanying methods useful for treating disorders arising from oxidative DNA damage, including oxidative DNA damage resulting from ionizing radiation or other therapy are described herein.

Abstract: A solution-cathode glow discharge mass spectrometry (SCGD-MS) apparatus comprises a SCGD source and a mass spectrometer. The SCGD source may comprise conductive rods, a power source, and a capillary. A method for ionizing an analyte comprises flowing an electrically conductive liquid onto a conductive rod, applying an electric potential to a second conductive rod such that a plasma discharge forms between the first conductive rod and the electrically conductive liquid to produce ions, and separating the ions in a mass spectrometer. The analyte may be a polypeptide that may be contacted with trypsin. The analyte may be a solid, liquid, gas, chemical complex, or ion in solution. The method may comprise sequencing the polypeptide.

Abstract: Mass spectrometry cartridge including a base in mechanical communication with a spray substrate holder, an absorbent pad between the base and the spray substrate holder, a translatable sample well holder interposed between the spray substrate holder and a top cover, the top cover configured to house a conductive element, wherein when the translatable sample well holder is in a first position, the translatable well holder is vertically above the absorbent pad, when the translatable sample well holder is in a second position, the translatable well holder is vertically above a spray substrate are disclosed. Methods of analyzing a sample are also disclosed.

Abstract: A device for extending the life of a battery, including an electrode having a metal portion, wherein the metal portion is selected from the group including lithium, calcium, magnesium, sodium, potassium and combinations thereof, an electrolyte permeable membrane, and a metal dendrite seeding material disposed between the electrode and the membrane. The electrode, the membrane and the metal dendrite seeding material are positioned in an electrolyte matrix. At least one dendrite extends from the electrode toward the electrolyte permeable membrane combines with at least one dendrite extending from the dendrite seeding material.

Abstract: Embodiments of the current invention include a hydrogel formed from crosslinked polyethylene glycol into which acrylated glucose oxidase has been immobilized through crosslinking to the gel. These hydrogels can be used to create hypoxia under ambient conditions for at least 72 hours and can be used to create hypoxic gradients. These embodiments permit the study of cells under a variety of hypoxic conditions.

Abstract: The present disclosure relates to certain compounds having binding affinity for Ku, and uses thereof. Specifically, the present disclosure relates to the use of Ku inhibitors as described herein in site-specific genome engineering technologies, including but not limited to CRISPR/Cas9, Zinc finger nuclease (ZFN), Transcription activator-like effector nuclease (TALEN), and meganuclease. The present disclosure also relates to kits useful for site-specific genome engineering that include at least one compound as described herein.

Abstract: Methods for directly measuring a patient's relative sensitivity to radiation therapy are provided. In particular, the methods provide for calculating a radiation sensitivity quotient for monocytes in culture. The methods can be incorporated into radiotherapy (RT) treatment planning systems, which are also provided. The methods can be used to optimize patient treatment plans, thereby developing patient-specific radiation treatment plans. Methods for treating a patient with radiotherapy with an optimized treatment plan are provided.

Abstract: A physical device interface for a virtual reality system is provided, comprising: a microprocessor board including a microprocessor, a plurality of control outputs, a first communication port and a second communication port; a plurality of receptacles configured to provide power to a corresponding plurality of physical devices; and a power board coupled to the plurality of control outputs and the plurality of receptacles, the power board including a plurality of channels controlled by the plurality of control outputs to provide power to the plurality of receptacles. The first communication port is configured to communicate with a computer for configuration of the interface and the second communication port is configured to communicate with another interface.

Abstract: A system comprising a processor in electrical communication with a network and a non-transitory memory having instructions that, in response to an execution by the processor, cause the processor to monitor a routing information base (“RIB”) of the network, identify a change in the RIB, calculate a probability of suspiciousness of the change in the RIB, and classify the change in the RIB based on a continuum of trust are disclosed. Methods of managing routers are also disclosed.

Abstract: The present disclosure provides a method and system including a non-confocal microscope with an attached imaging fiber optic for direct and real time in-situ visualization of mammalian microscopic structures for diagnostic and therapeutic uses.

Abstract: Embodiments of the present disclosure provide polypeptides, related materials and compositions, and methods for their use. In certain embodiments, the present disclosure provides a monomeric Tamm-Horsfall Protein polypeptide, or a biologically active truncation thereof. Other embodiments provide polynucleotides encoding a polypeptide described herein, nucleic acid expression vectors including the polynucleotides, and recombinant host cells including the expression vector. Yet other embodiments provide pharmaceutical compositions including a polypeptide described herein. Also provided are methods for treating a renal disease, disorder, or condition in a subject and/or modulating an immune response in a subject.